# Study of D3L-002 in Subjects With Advanced Solid Tumors

> **NCT07667842** · PHASE1 · RECRUITING · sponsor: **D3 Bio (Wuxi) Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** D3L-002

## Key facts

- **NCT ID:** NCT07667842
- **Lead sponsor:** D3 Bio (Wuxi) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-14
- **Primary completion:** 2027-11-12
- **Final completion:** 2028-02-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07667842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07667842, "Study of D3L-002 in Subjects With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07667842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*